Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
about
Optimizing the Clinical Use of VancomycinNovel pandemic influenza A (H1N1) and community-associated methicillin-resistant Staphylococcus aureus pneumonia.Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis.Procalcitonin is a marker of gram-negative bacteremia in patients with sepsis.Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearanceVancomycin 24-Hour Area under the Curve/Minimum Bactericidal Concentration Ratio as a Novel Predictor of Mortality in Methicillin-Resistant Staphylococcus aureus BacteremiaOptimizing the detection of methicillin-resistant Staphylococcus aureus with elevated vancomycin minimum inhibitory concentrations within the susceptible range.Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream InfectionsVancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections.Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot studyThe Nephrotoxicity of VancomycinRelationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: A pilot study.Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.Establishment of an AUC0-24 Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia.Intravenous Vancomycin Dosing in the Elderly: A Focus on Clinical Issues and Practical Application.Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.Assessment of linezolid prescriptions in three French hospitals.Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection?Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-analysis of Observational Studies.A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.A prospective trial on the use of trough concentration versus area under the curve (AUC) to determine therapeutic vancomycin dosing.Individualized Empiric Vancomycin Dosing in Neonates Using a Model-Based Approach.Pharmacokinetic/pharmacodynamic (PK/PD) Determinants of Vancomycin Efficacy in Enterococcal Bacteremia.Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin.[Pharmacokinetics and pharmacodynamics of antibiotics in intensive care].The ratio of pre-dialysis vancomycin trough serum concentration to minimum inhibitory concentration is associated with treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia.Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo simulation.
P2860
Q28069334-079E31DE-6889-4B83-AEB0-0C10E1B3127BQ30370676-AB1CB0F3-E269-4E0F-B361-474B608D0550Q35607636-DB1538DC-72BF-4657-830B-FD98EF697F78Q35670631-32B255CC-1481-4091-B392-D638C19E89ABQ36083619-0EA01689-82DA-4749-9BD3-409E06499100Q36089167-BFDB8BCA-B6F3-4655-B1AB-439646AF429AQ36888003-A43A9956-A680-4428-A875-44BE679652CBQ36981191-3D40E0D6-0F69-4295-B177-1A190A1EC053Q37287739-D3D37416-1EAD-4163-A114-43B5F0731CD8Q38258649-8F147B59-67D4-450C-ADF0-5826C8E6D6BEQ38545589-B887DFB4-1D9C-44F4-BA21-732F79EE51E7Q38648530-790FA0CE-457A-4A9F-8A67-F6765A499AC9Q38687487-B6D18007-CE03-4018-A141-778D36DB054BQ38690127-979529DD-4CB9-43C9-9858-881FD33B1BA8Q38738512-E38AB207-CDE2-4019-9C56-AB7D43D4171EQ38938708-9E02DBA0-DA84-4505-AF45-DFD4D16F94C0Q39017701-AA21B0AA-CF56-473C-B13D-4B3DDDD4380AQ39340850-FB72806B-6D2D-407B-B72C-A796C26D4767Q40356411-7B485916-139C-48AB-9D85-19A8B7496C9BQ40716347-7EF8AF28-E0E5-4E60-9212-D3FDA7EA8754Q40938813-74CD440D-3FFD-4DE2-A69F-990E4D3B8182Q41996750-983A0788-3BF9-47FD-A1C6-3DC0D89F4788Q46731557-65079C66-75E5-48A5-867F-4CE4904ED993Q47222670-7B73CD2E-4F99-455E-AA57-7A1C523E3C06Q47273967-B2103125-20E7-4264-99DB-596551FB5297Q47689239-AA0ECABA-D88C-4BE2-82C6-47D89FCAF861Q51751807-77B1BFC7-72E3-4F92-8B0E-55DC598DBDC6Q53704626-4CDACE67-20C4-45F2-A031-8659AB49B77FQ54957598-00A20B6B-19DC-43AA-B6C3-00509078D232
P2860
Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Vancomycin exposure in patient ...... nfections: how much is enough?
@en
Vancomycin exposure in patient ...... nfections: how much is enough?
@nl
type
label
Vancomycin exposure in patient ...... nfections: how much is enough?
@en
Vancomycin exposure in patient ...... nfections: how much is enough?
@nl
prefLabel
Vancomycin exposure in patient ...... nfections: how much is enough?
@en
Vancomycin exposure in patient ...... nfections: how much is enough?
@nl
P2093
P2860
P356
P1476
Vancomycin exposure in patient ...... nfections: how much is enough?
@en
P2093
Amanda Dihmess
Evan Zasowski
George L Drusano
Leon Cosler
Louise-Anne McNutt
Thomas P Lodise
Victoria Lazariu
P2860
P304
P356
10.1093/CID/CIU398
P407
P577
2014-05-27T00:00:00Z